title: Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials.
abstract: OBJECTIVE
  We evaluated the effect of external-beam radiation therapy on disease-specific survival (death from causes related to prostate cancer) and overall survival in men with clinically localized prostate cancer.
  
  
  METHODS
  From 1975 to 1992, 1,465 men with clinically localized prostate cancer received radiation therapy on four Radiation Therapy Oncology Group phase III randomized trials and were pooled for this analysis. No one received androgen-deprivation therapy with his initial treatment. All original histology had central pathologic review for grading using the Gleason classification system. Total delivered radiation dose ranged from 60 to 78 Gy (median, 68.4 Gy). The median follow-up time was 8 years.
  
  
  RESULTS
  A Cox regression model revealed that Gleason score was an independent predictor of disease-specific survival and overall survival. The 10-year disease-specific survival rates by Gleason score were as follows: score of 2 through 5, 85%; score of 6, 79%; score of 7, 62%; and score of 8 through 10, 43%. Stratifying outcome by this important prognostic factor revealed that higher radiation dose was a significant predictor for improved disease-specific survival and overall survival only for those patients whose cancers had Gleason scores of 8 through 10 (P <.05). After adjusting for clinical T stage, nodal status, and age, treating with a higher radiation dose was associated with a 29% lower relative risk of death from prostate cancer and 27% reduced mortality rate (P <.05).
  
  
  CONCLUSIONS
  These data demonstrate that higher-dose radiation therapy can significantly reduce the risk of dying from prostate cancer in men with clinically localized disease. This survival benefit is restricted to men with poorly differentiated cancers.
authors.affiliation: Kimmel Cancer Center, Thomas Jefferson University Hospital, Philadelphia, PA 19107-5097, USA. richard.valicenti@mail.tju.edu
authors.forename: R
authors.initials: R
authors.lastname: Valicenti
authors.forename: J
authors.initials: J
authors.lastname: Lu
authors.forename: M
authors.initials: M
authors.lastname: Pilepich
authors.forename: S
authors.initials: S
authors.lastname: Asbell
authors.forename: D
authors.initials: D
authors.lastname: Grignon
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D017326:Clinical Trials, Phase III as Topic; D018450:Disease Progression; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis